KIORA PHARMACEUTICALS INC — Director's Dealing 2020

Aug 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2020-08-04

Reporting Person: Mann Brenda (VP of Research & Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-08-04	Common Stock	F	92	$4.11	Disposed	17753	Direct

Footnotes

F1: Sale of shares to cover taxes due on restricted stock that vested on 08/01/2020.